Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix.
Nano Lett
; 12(6): 3213-7, 2012 Jun 13.
Article
en En
| MEDLINE
| ID: mdl-22554317
ABSTRACT
A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (â¼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Proliferación Celular
/
Matriz Extracelular
/
Nanocápsulas
/
Proteína-Lisina 6-Oxidasa
/
Neoplasias Mamarias Experimentales
Límite:
Animals
Idioma:
En
Año:
2012
Tipo del documento:
Article